| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Abrocitinib (JAN/USAN); Cibinqo (TN) | ||||||
| Product | CIBINQO (Pfizer Laboratories Div Pfizer), CIBINQO (U.S. Pharmaceuticals) | ||||||
| Formula | C14H21N5O2S | ||||||
| Exact mass | 323.1416 | ||||||
| Mol weight | 323.4138 | ||||||
| Structure |  | ||||||
| Class | Anti-inflammatory DG01985 Disease modifying anti-rheumatic drug (DMARD) DG02020 JAK inhibitor Metabolizing enzyme substrate DG01642 CYP2C9 substrate DG01639 CYP2C19 substrate | ||||||
| Remark |
| ||||||
| Efficacy | Anti-inflammatory, Janus kinase (JAK) inhibitor | ||||||
| Disease | Atopic dermatitis [DS:H01358] | ||||||
| Comment | Treatment of atopic dermatitis | ||||||
| Target | JAK1 [HSA:3716] [KO:K11217] | ||||||
| Pathway |
| ||||||
| Metabolism | Enzyme: CYP2C19 [HSA:1557], CYP2C9 [HSA:1559] | ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AH Agents for dermatitis, excluding corticosteroids D11AH08 Abrocitinib D11400 Abrocitinib (JAN/USAN) <JP/US> Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 44 Allergic agents 449 Miscellaneous 4490 Miscellaneous D11400 Abrocitinib (JAN/USAN) Drug groups [BR:br08330] Anti-inflammatory DG01985 Disease modifying anti-rheumatic drug (DMARD) DG02020 JAK inhibitor D11400 Abrocitinib Metabolizing enzyme substrate DG01642 CYP2C9 substrate D11400 Abrocitinib DG01639 CYP2C19 substrate D11400 Abrocitinib Drug classes [BR:br08332] Immunological agent DG02020 JAK inhibitor D11400 Abrocitinib Antirheumatic agent DG01985 Disease modifying anti-rheumatic drug (DMARD) D11400 Abrocitinib Target-based classification of drugs [BR:br08310] Protein kinases Non-receptor tyrosine kinases JAK family JAK1 D11400 Abrocitinib (JAN/USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11400 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D11400 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D11400 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11400 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D11400 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 22 1 C8y C 12.9500 -16.9400 2 C8y C 12.9500 -18.3400 3 N5x N 11.7600 -19.0400 4 C8x C 10.5000 -18.3400 5 N5x N 10.5000 -16.9400 6 C8y C 11.7600 -16.2400 7 N4x N 14.2815 -18.7726 8 C8x C 15.1044 -17.6400 9 C8x C 14.2815 -16.5074 10 N1c N 11.7772 -14.8401 11 C1a C 12.9851 -14.1624 12 C1y C 10.5608 -14.1176 13 C1x C 10.2211 -12.7842 14 C1y C 8.8877 -13.1238 15 C1x C 9.2273 -14.4573 16 N1b N 7.6710 -12.4015 17 S4a S 6.4772 -13.0717 18 C1b C 5.3056 -12.3762 19 O3c O 5.7772 -14.2841 20 O3c O 7.1772 -14.2841 21 C1b C 4.0900 -13.0587 22 C1a C 2.8784 -12.3392 BOND 24 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 2 7 1 8 7 8 1 9 8 9 2 10 1 9 1 11 6 10 1 12 10 11 1 13 12 10 1 #Up 14 12 13 1 15 13 14 1 16 14 15 1 17 12 15 1 18 14 16 1 #Up 19 16 17 1 20 17 18 1 21 17 19 2 22 17 20 2 23 18 21 1 24 21 22 1 |